Company news

Zevra Therapeutics, Inc. news in 2020

Zevra Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

KemPharm Announces 1-for-16 Reverse Stock Split

December 22, 2020

KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder

December 21, 2020

KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA

December 1, 2020

REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event

November 29, 2020

KemPharm Provides Update on Development Pipeline

November 22, 2020

KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event

November 17, 2020

KemPharm Reports Third Quarter 2020 Financial Results

October 28, 2020

KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call

October 25, 2020

KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting

October 21, 2020

KemPharm and Corium Expand Relationship with New Consultation Services Agreement

October 4, 2020

KemPharm Files Preliminary Proxy for Special Meeting of Stockholders

September 24, 2020

KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies

September 9, 2020

KemPharm to Present at Upcoming September Investor Conferences

September 1, 2020

KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA

August 13, 2020

Decks in 2020